Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | Options available to patients with TP53-mutated MDS beyond stem cell transplantation

Magnus Tobiasson • 20 Oct 2023
COSTEM 2023
Myelodysplastic Syndromes Antibodies Azacitidine Checkpoint inhibitors Decitabine Eprenetapopt Venetoclax

Magnus Tobiasson, MBBS, Karolinska Institute, Solna, Sweden, briefly discusses treatment options available to patients with TP53-mutated myelodysplastic syndromes (MDS) beyond stem cell transplantation (SCT), including hypomethylating agents (HMAs), venetoclax, and various checkpoint inhibitors. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Magnus Tobiasson

1:25
Should patients with TP53-mutated MDS receive stem cell transplant?
Magnus Tobiasson • 20 Oct 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals